紫杉醇联合顺铂化疗方案对进展期食管癌患者HMGB1、CEA、SCC-Ag水平的影响
Effect of the HMGB1、CEA and SCC-Ag by paclitaxel combined with cisplatin chemotherapy in advanced esophageal cancer
胡伟 1丁叔波 2王红勇 3何慧娟 1廖小方 1徐万苏1
作者信息
- 1. 浙江省衢州市人民医院 放疗科,浙江 衢州 324000
- 2. 浙江省金华市中心医院 放疗科,浙江 金华 321099
- 3. 吉林大学第二医院 放疗科,吉林 长春 130041
- 折叠
摘要
目的 探究紫杉醇联合顺铂化疗方案对进展期食管癌患者高迁移率族蛋白1(HMGB1)、癌胚抗原(CEA)及鳞状上皮细胞癌抗原(SCC-Ag)水平影响.方法 选择衢州市人民医院、金华市中心医院、吉林大学第二医院收治的进展期食管癌患者43例,分为实验组及对照组.对照组19例予手术治疗联合术后化疗;实验组24例予手术治疗联合术前及术后化疗.比较2组治疗前后临床疗效及高迁移率族蛋白1(HMGB1)、癌胚抗原(CEA)以及鳞状上皮细胞癌抗原(SCC-Ag)水平变化.结果 实验组总有效率91.7%高于对照组57.9%,差异有统计学意义(P<0.05);治疗后,2组血清SCC-Ag,CEA及HMGB1水平均下降,同对照组比较,实验组SCC-Ag,CEA及HMGB1水平较低,差异有统计学意义(P<0.05);2组不良反应比较后,差异无统计学意义.结论 紫杉醇联合顺铂,在治疗进展期食管癌患者时效果好,推测与降低患者血清SCC-Ag,CEA及HMGB1水平有关.
Abstract
Objective To investigate the effect of the high mobility group protein 1 (HMGB1), cancer embryonic antigen (CEA) and squamous cell carcinoma antigen ( SCC-Ag) by paclitaxel combined with cisplatin chemotherapy in the treatment of advanced esophageal cancer patients .Methods 43 cases advanced esophageal cancer patients from our hospital were selected and randomly divided into the control group and the experiment group.19 cases in the control group were treated by surgery combined with postoperative chemotherapy , 24 cases in the experimental group were treated with surgery and chemotherapy.The clinical efficacy and high mobility group protein 1 ( HMGB1 ) , cancer embryonic antigen ( CEA ) and squamous cell carcinoma antigen ( SCC-Ag ) levels were compared between the two groups before and after treatment.Results The total effective rate of the experimental group was (91.7%) higher than that of the control group (57.9%), the difference was statistically significant (P <0.05).After treatment, the serum levels of SCC-Ag, CEA and HMGB1 were decreased in the two groups, compared with the control group, the experimental group SCC-Ag, CEA and HMGB1 levels were lower, the difference was statistically significant ( P <0.05 ) .There was no significant difference in adverse reactions between the two groups.Conclusion Paclitaxel combined with cisplatin in the treatment of advanced esophageal cancer patients with good results, presumably with the decrease of serum SCC-Ag, CEA and HMGB1 levels in patients with.
关键词
紫杉醇/顺铂/联合/进展期食管癌/HMGB1/CEA/SCC-AgKey words
paclitaxel/cisplatin/combine/advanced esophageal cancer/HMGB1/CEA/SCC-Ag引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据